Viva Biotech Holdings (HKSE:01873) Debt-to-EBITDA : 9.83 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Viva Biotech Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Viva Biotech Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$1,042 Mil. Viva Biotech Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$1,040 Mil. Viva Biotech Holdings's annualized EBITDA for the quarter that ended in Dec. 2023 was HK$212 Mil. Viva Biotech Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 9.83.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Viva Biotech Holdings's Debt-to-EBITDA or its related term are showing as below:

HKSE:01873' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -31.71 Med: 0.13 Max: 5.74
Current: 5.74

During the past 8 years, the highest Debt-to-EBITDA Ratio of Viva Biotech Holdings was 5.74. The lowest was -31.71. And the median was 0.13.

HKSE:01873's Debt-to-EBITDA is ranked worse than
84.31% of 274 companies
in the Biotechnology industry
Industry Median: 1.31 vs HKSE:01873: 5.74

Viva Biotech Holdings Debt-to-EBITDA Historical Data

The historical data trend for Viva Biotech Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viva Biotech Holdings Debt-to-EBITDA Chart

Viva Biotech Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

0.16

-13.26

3.88

-31.71

5.74

Viva Biotech Holdings Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial									3.39	11.93	-6.83	6.18	9.83

Competitive Comparison of Viva Biotech Holdings's Debt-to-EBITDA

For the Biotechnology subindustry, Viva Biotech Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viva Biotech Holdings's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Viva Biotech Holdings's Debt-to-EBITDA falls into.

Viva Biotech Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Viva Biotech Holdings's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1041.76	+	1039.939)	/	362.965
	=	5.74

Viva Biotech Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1041.76	+	1039.939)	/	211.858
	=	9.83

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.

Viva Biotech Holdings (HKSE:01873) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Viva Biotech Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Viva Biotech Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Viva Biotech Holdings (HKSE:01873) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viva Biotech Holdings (HKSE:01873) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

VBIZF:USA VB0:Germany

Address

735 Ziping Road, Pudong New District, Zhoupu Town, Shanghai, CHN, 201318

Website

https://www.vivabiotech.com

Viva Biotech Holdings is an integrated drug discovery platform. The company's operating segment includes Drug discovery services and Contract Development Manufacture Organisation (CDMO) and commercialisation services. It generates maximum revenue from the Contract Development Manufacture Organisation (CDMO) and commercialisation services segment. The Contract Development Manufacture Organisation ("CDMO") and commercialisation services segment includes contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations.

Executives

Mao Chen Cheney	2101 Beneficial owner
Wu John Jiong	2201 Interest of corporation controlled by you
Fenghe Harvest Ltd	2101 Beneficial owner
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Mao Jun	2501 Other
Temasek Holdings (private) Limited	2201 Interest of corporation controlled by you
Zhou Min	2202 Interest of your spouse
Intertrust (singapore) Ltd.	2301 Trustee
Z&m International Holdings Limited	2201 Interest of corporation controlled by you
Zhang And Sons Limited	2101 Beneficial owner

Viva Biotech Holdings (HKSE:01873) Headlines

No Headlines